Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Invion ( (AU:IVX) ) just unveiled an announcement.
Invion Limited announced positive findings from the Safety Review Committee regarding its Phase I/II non-melanoma skin cancer trial using INV043. The trial showed no adverse events and indicated a reduction in lesion size post-treatment, with patients experiencing no pain, a significant advantage over existing treatments. The trial also highlighted INV043’s potential as a diagnostic tool, with cancer cells fluorescing under violet light, aiding in more precise surgical interventions. These findings support the continuation of the trial and contribute to the upcoming anogenital cancer trial in collaboration with the Peter MacCallum Cancer Centre.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on developing innovative treatments for cancer. The company is known for its lead drug candidate, INV043, which is used in the treatment of non-melanoma skin cancer and other cancer types.
Average Trading Volume: 82,664
Technical Sentiment Signal: Sell
Current Market Cap: A$7.37M
See more data about IVX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue